These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1836917)

  • 61. Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication.
    Katar S; Taskesen M; Okur N
    Pediatr Int; 2010 Jun; 52(3):488-9. PubMed ID: 20723124
    [No Abstract]   [Full Text] [Related]  

  • 62. Can ondansetron hydrochloride (Zofran) enhance the nephrotoxic potential of other drugs?
    Aamdal S
    Ann Oncol; 1992 Nov; 3(9):774. PubMed ID: 1450070
    [No Abstract]   [Full Text] [Related]  

  • 63. Frequency and severity of promethazine adverse event reports obligated the ISMP alert.
    Cohen MR
    Jt Comm J Qual Patient Saf; 2010 Mar; 36(3):143-4. PubMed ID: 20235416
    [No Abstract]   [Full Text] [Related]  

  • 64. Ponatinib pulled off market over safety issues.
    Dalzell MD
    Manag Care; 2013 Dec; 22(12):42-3. PubMed ID: 24558672
    [No Abstract]   [Full Text] [Related]  

  • 65. Ondansetron (Zofran) for Pediatric Gastroenteritis.
    Hanuscin C; Hassel J; Khan A
    Acad Emerg Med; 2021 Jan; 28(1):135-137. PubMed ID: 32506567
    [No Abstract]   [Full Text] [Related]  

  • 66. Ondansetron to prevent vomiting after cancer chemotherapy.
    Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531
    [No Abstract]   [Full Text] [Related]  

  • 67. Ondansetron HCL (Zofran TM, Glaxo).
    Frankiewicz V; Farrington E
    Pediatr Nurs; 1992; 18(4):385-6. PubMed ID: 1387704
    [No Abstract]   [Full Text] [Related]  

  • 68. [Ondansetron--a 5HT 3 receptor antagonist for the treatment of nausea and vomiting induced by cytostatics and radiotherapy].
    Herrstedt J; Ersbøll J; Dombernowsky P
    Ugeskr Laeger; 1991 Apr; 153(18):1292-5. PubMed ID: 1827555
    [No Abstract]   [Full Text] [Related]  

  • 69. [New, in Austria registered specialty drugs. Zofran (Ondansetron, Glaxo)].
    Erben M
    Wien Klin Wochenschr; 1991; 103(19):594-601. PubMed ID: 1836917
    [No Abstract]   [Full Text] [Related]  

  • 70. Ondansetron to prevent chemotherapy-induced vomiting.
    Drug Ther Bull; 1992 Mar; 30(6):21-3. PubMed ID: 1534293
    [No Abstract]   [Full Text] [Related]  

  • 71. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety of ondansetron.
    Smith RN
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S47-50; discussion S51-4. PubMed ID: 2533899
    [TBL] [Abstract][Full Text] [Related]  

  • 73. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.